FrancophonIA/ELRC3.0 huggingface dataset:
English: In patients with mild to moderate hepatic impairment without cholestasis, the maximum recommended dose is 80 mg valsartan, and therefore, Exforge HCT is not suitable in this group of patients (see sections 4.2, 4.3 and 5.2).
Estonian: Ilma kolestaasita kerge kuni mõõduka maksakahjustusega patsientidel on valsartaani maksimaalne soovitatav annus 80 mg ning seetõttu ei ole Exforge HCT selle patsiendigrupi jaoks sobiv (vt lõigud 4.2, 4.3 ja 5.2).
English: Excessive hypotension, including orthostatic hypotension, was seen in 1.7% of patients treated with the maximum dose of Exforge HCT (10 mg/320 mg/25 mg) compared to 1.8% of valsartan/hydrochlorothiazide (320 mg/25 mg) patients, 0.4% of amlodipine/valsartan (10 mg/320 mg) patients, and 0.2% of hydrochlorothiazide/amlodipine (25 mg/10 mg) patients in a controlled trial in patients with moderate to severe uncomplicated hypertension.
Estonian: Ülemäärast vererõhu langust (sh ortostaatilist hüpotensiooni) täheldati 1,7% patsientidest, kes said Exforge HCT'd maksimaalses annuses (10 mg/320 mg/25 mg), võrreldes 1,8%-ga valsartaani/hüdroklorotiasiidi (320 mg/25 mg), 0,4%-ga amlodipiini/valsartaani (10 mg/320 mg) ja 0,2%-ga hüdroklorotiasiidi/amlodipiini (25 mg/10 mg) saanud patsientidel kontrollitud uuringus mõõduka kuni raske komplitseerumata hüpertensiooniga patsientidel.
English: The following adverse reactions, listed by MedDRA System Organ Class and frequency, concern Exforge HCT (amlodipine/valsartan/HCT) and amlodipine, valsartan and HCT individually.
Estonian: Järgmisi MedDRA organsüsteemi klassi ja esinemissageduse järgi loetletud kõrvaltoimeid on täheldatud Exforge HCT (amlodipiin/valsartaan/hüdroklorotiasiid) ning amlodipiini, valsartaani ja hüdroklorotiasiidi eraldi kasutamisel.
English: If you stop taking Exforge HCT
Estonian: Kui te lõpetate Exforge HCT võtmise
English: • ACE inhibitors or aliskiren (see also information under the headings “Do not take Exforge HCT” and “Warnings and precautions”).
Estonian: Nendeks on kaaliumipreparaadid või kaaliumi sisaldavad soolaasendajad, kaaliumisäästvad ravimid ja hepariin; AKE inhibiitorid või aliskireen (vt ka teavet lõikudes „Ärge võtke Exforge HCT'd“ ja „Hoiatused ja ettevaatusabinõud“).
English: Furthermore, concomitant use of Exforge HCT and NSAIDs may lead to worsening of renal function and an increase in serum potassium.
Estonian: Peale selle võib Exforge HCT ja MSPVA'te samaaegsel kasutamisel tekkida neerufunktsiooni halvenemine ning kaaliumi kontsentratsiooni tõus seerumis.
English: If any of the above applies to you, do not take Exforge HCT and talk to your doctor.
Estonian: Kui midagi ülalloetletust kehtib teie kohta, ärge Exforge HCT'd võtke ja rääkige sellest oma arstile.
English: Exforge HCT 5 mg/160 mg/12.5 mg film-coated tablets Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets Exforge HCT 5 mg/160 mg/25 mg film-coated tablets Exforge HCT 10 mg/160 mg/25 mg film-coated tablets Exforge HCT 10 mg/320 mg/25 mg film-coated tablets
Estonian: Exforge HCT 5 mg/160 mg/12,5 mg õhukese polümeerikattega tabletid Exforge HCT 10 mg/160 mg/12,5 mg õhukese polümeerikattega tabletid Exforge HCT 5 mg/160 mg/25 mg õhukese polümeerikattega tabletid Exforge HCT 10 mg/160 mg/25 mg õhukese polümeerikattega tabletid Exforge HCT 10 mg/320 mg/25 mg õhukese polümeerikattega tabletid
English: Caution is advised in patients with heart failure and coronary artery disease, particularly at the maximum dose of Exforge HCT, 10 mg/320 mg/25 mg, since available data in these patient populations is limited.
Estonian: Ettevaatlik peab olema südamepuudulikkuse ja koronaartõvega patsientide ravimisel, eriti kui kasutatakse Exforge HCT maksimaalset annust 10 mg/320 mg/25 mg, sest nende patsientide kohta saadud andmed on piiratud.
English: At week 8, the mean reductions in systolic/diastolic blood pressure were 39.7/24.7 mmHg with Exforge HCT, 32.0/19.7 mmHg with valsartan/hydrochlorothiazide, 33.5/21.5 mmHg with amlodipine/valsartan, and 31.5/19.5 mmHg with amlodipine/hydrochlorothiazide.
Estonian: 8. nädalal oli süstoolse/diastoolse vererõhu keskmine langus 39,7/24,7 mmHg Exforge HCT, 32,0/19,7 mmHg valsartaani/hüdroklorotiasiidi, 33,5/21,5 mmHg amlodipiini/valsartaani ja 31,5/19,5 mmHg amlodipiini/hüdroklorotiasiidi puhul.
English: In patients with mild to moderate hepatic impairment without cholestasis, the maximum recommended dose is 80 mg valsartan and therefore Exforge HCT is not suitable in this group of patients (see sections 4.3, 4.4 and 5.2).
Estonian: Ilma kolestaasita kerge kuni mõõduka maksakahjustuse korral on valsartaani maksimaalne soovitatav annus 80 mg ning seetõttu ei sobi Exforge HCT sellele patsientide rühmale (vt lõigud 4.3, 4.4 ja 5.2).
English: When switching eligible hypertensive patients (see section 4.1) with hepatic impairment to Exforge HCT, the lowest available dose of the amlodipine component should be used.
Estonian: Viies sobivaid hüpertensiivseid maksakahjustusega patsiente (vt lõik 4.1) üle Exforge HCT-ravile, tuleb kasutada kombinatsioonravis amlodipiini minimaalset saadaolevat annust.
English: Due to the valsartan component, Exforge HCT is contraindicated in patients with hepatic impairment (see sections 4.2 and 4.3).
Estonian: Valsartaani sisalduse tõttu on Exforge HCT vastunäidustatud maksakahjustusega patsientidel (vt lõigud 4.2 ja 4.3).
English: This is a disease in which the adrenal glands make too much of the hormone aldosterone If this applies to you, the use of Exforge HCT is not recommended.
Estonian: See on haigus, mille puhul neerupealised toodavad liiga palju aldosterooniks nimetatud hormooni.
English: If hypokalaemia develops during hydrochlorothiazide therapy, Exforge HCT should be discontinued until stable correction of the potassium balance.
Estonian: Kui hüpokaleemia tekib ravi ajal hüdroklorotiasiidiga, tuleb Exforge HCT manustamine lõpetada kuni kaaliumitaseme stabiliseerumiseni.
English: The maximum recommended dose of Exforge HCT is 10 mg/320 mg/25 mg.
Estonian: Exforge HCT maksimaalne soovitatav annus on 10 mg/320 mg/25 mg.
English: How to take Exforge HCT
Estonian: Kuidas Exforge HCT'd võtta
English: Grapefruit and grapefruit juice should not be consumed by people who are prescribed Exforge HCT.
Estonian: Inimesed, kellele on välja kirjutatud Exforge HCT'd, ei tohiks tarvitada greipfruuti ega greipfruudimahla.
English: The dose of Exforge HCT should be based on the doses of the individual components of the combination at the time of switching.
Estonian: Üleminekul peaks Exforge HCT annus põhinema kombinatsiooni üksikute komponentide annustel.
English: Exforge HCT 5 mg/160 mg/12.5 mg film-coated tablets Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets Exforge HCT 5 mg/160 mg/25 mg film-coated tablets Exforge HCT 10 mg/160 mg/25 mg film-coated tablets Exforge HCT 10 mg/320 mg/25 mg film-coated tablets amlodipine/valsartan/hydrochlorothiazide
Estonian: Exforge HCT 5 mg/160 mg/12,5 mg õhukese polümeerikattega tabletid Exforge HCT 10 mg/160 mg/12,5 mg õhukese polümeerikattega tabletid Exforge HCT 5 mg/160 mg/25 mg õhukese polümeerikattega tabletid Exforge HCT 10 mg/160 mg/25 mg õhukese polümeerikattega tabletid Exforge HCT 10 mg/320 mg/25 mg õhukese polümeerikattega tabletid amlodipiin/valsartaan/hüdroklorotiasiid (amlodipinum/valsartanum/hydrochlorothiazidum)
English: Due to the valsartan component, Exforge HCT is contraindicated in patients with severe hepatic impairment (see section 4.3).
Estonian: Valsartaani sisalduse tõttu on Exforge HCT vastunäidustatud raske maksakahjustusega patsientidel (vt lõik 4.3).
English: Caution is advised in patients with heart failure and coronary artery disease, particularly at the maximum dose of Exforge HCT, 10 mg/320 mg/25 mg.
Estonian: Ettevaatlik peab olema südamepuudulikkuse ja koronaartõvega patsientide ravimisel, eriti kui kasutatakse Exforge HCT maksimaalset annust 10 mg/320 mg/25 mg.
English: There is no experience of overdose with Exforge HCT.
Estonian: Exforge HCT üleannustamise kogemus puudub.
English: What Exforge HCT looks like and contents of the pack Exforge HCT 5 mg/160 mg/12.5 mg film-coated tablets are white, oval tablets with “NVR” on one side and “VCL” on the other side.
Estonian: Kuidas Exforge HCT välja näeb ja pakendi sisu Exforge HCT 5 mg/160 mg/12,5 mg õhukese polümeerikattega tabletid on valged, ovaalsed tabletid, mille ühel poolel on kiri „NVR” ja teisel „VCL”.
English: Treatment with Exforge HCT should only start after correction of hypokalaemia and any coexisting hypomagnesaemia.
Estonian: Ravi Exforge HCT'ga tohib alustada ainult pärast hüpokaleemia ja samaaegse hüpomagneseemia korrigeerimist.
English: No dose adjustment of Exforge HCT is required for patients with mild to moderate renal impairment (GFR ≥30 ml/min/1.73 m
Estonian: Kerge kuni mõõduka neerukahjustusega patsientidel (GFR ≥30 ml/min/1,73 m 2) ei ole vaja Exforge
English: Exforge HCT 10 mg/320 mg/25 mg film-coated tablets
Estonian: Exforge HCT 10 mg/320 mg/25 mg õhukese polümeerikattega tabletid
English: How to store Exforge HCT
Estonian: Kuidas Exforge HCT'd säilitada
English: Exforge HCT 5 mg/160 mg/25 mg film-coated tablets are yellow, oval tablets with “NVR” on one side and “VEL” on the other side.
Estonian: Exforge HCT 5 mg/160 mg/25 mg õhukese polümeerikattega tabletid on kollased, ovaalsed tabletid, mille ühel poolel on kiri „NVR” ja teisel „VEL”.
English: Exforge HCT 10 mg/320 mg/25 mg film-coated tablets are brown-yellow, oval tablets with “NVR” on one side and “VFL” on the other side.
Estonian: Exforge HCT 10 mg/320 mg/25 mg õhukese polümeerikattega tabletid on pruunikaskollased, ovaalsed tabletid, mille ühel poolel on kiri „NVR” ja teisel „VFL”.
English: Exforge HCT can be used by people aged 65 years and over at the same dose as for other adults and in the same way as they have already taken the three substances called amlodipine, valsartan and hydrochlorothiazide.
Estonian: 65-aastased ja vanemad inimesed võivad Exforge HCT'd kasutada samades annustes nagu teised täiskasvanud ning samal viisil nagu nad on siiamaani võtnud kolme toimeainet, milleks on amlodipiin, valsartaan ja hüdroklorotiasiid.. Eakatel patsientidel, iseäranis neil, kes võtavad Exforge HCT maksimaalset annust (10 mg/320 mg/25 mg), tuleks regulaarselt mõõta vererõhku.
English: EU/1/09/569/007 280 film-coated tablets
Estonian: EU/1/09/569/007 280 õhukese polümeerikattega tabletti
English: EU/1/09/569/043 280 film-coated tablets
Estonian: EU/1/09/569/043 280 õhukese polümeerikattega tabletti
English: EU/1/09/569/031 280 film-coated tablets
Estonian: EU/1/09/569/031 280 õhukese polümeerikattega tabletti
English: EU/1/09/569/027 30 film-coated tablets
Estonian: EU/1/09/569/027 30 õhukese polümeerikattega tabletti
English: Exforge HCT 10 mg/320 mg/25 mg film-coated tablets The active substances of Exforge HCT are amlodipine (as amlodipine besylate), valsartan and hydrochlorothiazide.
Estonian: Exforge HCT 10 mg/320 mg/25 mg õhukese polümeerikattega tabletid Exforge HCT toimeained on amlodipiin (amlodipiinbesülaadina), valsartaan ja hüdroklorotiasiid.
English: EU/1/09/569/016 56 film-coated tablets
Estonian: EU/1/09/569/016 56 õhukese polümeerikattega tabletti
English: EU/1/09/569/042 98 film-coated tablets
Estonian: EU/1/09/569/042 98 õhukese polümeerikattega tabletti
English: EU/1/09/569/026 28 film-coated tablets
Estonian: EU/1/09/569/026 28 õhukese polümeerikattega tabletti
English: EU/1/09/569/055 280 film-coated tablets
Estonian: EU/1/09/569/055 280 õhukese polümeerikattega tabletti
English: EU/1/09/569/004 56 film-coated tablets
Estonian: EU/1/09/569/004 56 õhukese polümeerikattega tabletti
English: EU/1/09/569/041 90 film-coated tablets
Estonian: EU/1/09/569/041 90 õhukese polümeerikattega tabletti
English: EU/1/09/569/018 98 film-coated tablets
Estonian: EU/1/09/569/018 98 õhukese polümeerikattega tabletti
English: EU/1/09/569/054 98 film-coated tablets
Estonian: EU/1/09/569/054 98 õhukese polümeerikattega tabletti
English: EU/1/09/569/005 90 film-coated tablets
Estonian: EU/1/09/569/005 90 õhukese polümeerikattega tabletti
English: EU/1/09/569/040 56 film-coated tablets
Estonian: EU/1/09/569/040 56 õhukese polümeerikattega tabletti
English: EU/1/09/569/038 28 film-coated tablets
Estonian: EU/1/09/569/038 28 õhukese polümeerikattega tabletti
English: Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets are pale yellow, oval tablets with “NVR” on one side and “VDL” on the other side.
Estonian: Exforge HCT 10 mg/160 mg/12,5 mg õhukese polümeerikattega tabletid on kahvatukollased, ovaalsed tabletid, mille ühel poolel on kiri „NVR” ja teisel „VDL”.
English: EU/1/09/569/001 14 film-coated tablets
Estonian: EU/1/09/569/001 14 õhukese polümeerikattega tabletti
English: Exforge HCT 10 mg/160 mg/25 mg film-coated tablets
Estonian: Exforge HCT 10 mg/160 mg/25 mg õhukese polümeerikattega tabletid
English: EU/1/09/569/006 98 film-coated tablets
Estonian: EU/1/09/569/006 98 õhukese polümeerikattega tabletti
English: Exforge HCT 5 mg/160 mg/25 mg film-coated tablets
Estonian: Exforge HCT 5 mg/160 mg/25 mg õhukese polümeerikattega tabletid
English: EU/1/09/569/053 90 film-coated tablets
Estonian: EU/1/09/569/053 90 õhukese polümeerikattega tabletti
English: EU/1/09/569/030 98 film-coated tablets
Estonian: EU/1/09/569/030 98 õhukese polümeerikattega tabletti
English: EU/1/09/569/019 280 film-coated tablets
Estonian: EU/1/09/569/019 280 õhukese polümeerikattega tabletti
English: Exforge HCT 5 mg/160 mg/12.5 mg film-coated tablets
Estonian: Exforge HCT 5 mg/160 mg/12,5 mg õhukese polümeerikattega tabletid
English: Exforge HCT 10 mg/320 mg/25 mg film-coated tablets amlodipine/valsartan/hydrochlorothiaziade
Estonian: Exforge HCT 10 mg/320 mg/25 mg õhukese polümeerikattega tabletid amlodipinum/valsartanum/hydrochlorothiazidum
English: EU/1/09/569/029 90 film-coated tablets
Estonian: EU/1/09/569/029 90 õhukese polümeerikattega tabletti
English: EU/1/09/569/049 14 film-coated tablets
Estonian: EU/1/09/569/049 14 õhukese polümeerikattega tabletti
English: Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets
Estonian: Exforge HCT 10 mg/160 mg/12,5 mg õhukese polümeerikattega tabletid
English: EU/1/09/569/052 56 film-coated tablets
Estonian: EU/1/09/569/052 56 õhukese polümeerikattega tabletti
English: EU/1/09/569/025 14 film-coated tablets
Estonian: EU/1/09/569/025 14 õhukese polümeerikattega tabletti
English: EU/1/09/569/014 28 film-coated tablets
Estonian: EU/1/09/569/014 28 õhukese polümeerikattega tabletti
English: EU/1/09/569/015 30 film-coated tablets
Estonian: EU/1/09/569/015 30 õhukese polümeerikattega tabletti
English: EU/1/09/569/037 14 film-coated tablets
Estonian: EU/1/09/569/037 14 õhukese polümeerikattega tabletti
English: EU/1/09/569/003 30 film-coated tablets
Estonian: EU/1/09/569/003 30 õhukese polümeerikattega tabletti
English: EU/1/09/569/017 90 film-coated tablets
Estonian: EU/1/09/569/017 90 õhukese polümeerikattega tabletti
English: Exforge HCT 10 mg/160 mg/25 mg film-coated tablets are brown-yellow, oval tablets with “NVR” on one side and “VHL” on the other side.
Estonian: Exforge HCT 10 mg/160 mg/25 mg õhukese polümeerikattega tabletid on pruunikaskollased, ovaalsed tabletid, mille ühel poolel on kiri „NVR” ja teisel „VHL”.
English: EU/1/09/569/051 30 film-coated tablets
Estonian: EU/1/09/569/051 30 õhukese polümeerikattega tabletti
English: EU/1/09/569/002 28 film-coated tablets
Estonian: EU/1/09/569/002 28 õhukese polümeerikattega tabletti
English: EU/1/09/569/056 56 x 1 film-coated tablet (unit dose) EU/1/09/569/057 98 x 1 film-coated tablet (unit dose) EU/1/09/569/058 280 x 1 film-coated tablet (unit dose)
Estonian: EU/1/09/569/056 56 x 1 õhukese polümeerikattega tablett (üksikannus) EU/1/09/569/057 98 x 1 õhukese polümeerikattega tablett (üksikannus) EU/1/09/569/058 280 x 1 õhukese polümeerikattega tablett (üksikannus)
English: Exforge HCT 5 mg/160 mg/25 mg film-coated tablets The active substances of Exforge HCT are amlodipine (as amlodipine besylate), valsartan and hydrochlorothiazide.
Estonian: Exforge HCT 5 mg/160 mg/25 mg õhukese polümeerikattega tabletid Exforge HCT toimeained on amlodipiin (amlodipiinbesülaadina), valsartaan ja hüdroklorotiasiid.
English: EU/1/09/569/032 56 x 1 film-coated tablet (unit dose) EU/1/09/569/033 98 x 1 film-coated tablet (unit dose) EU/1/09/569/034 280 x 1 film-coated tablet (unit dose)
Estonian: EU/1/09/569/032 56 x 1 õhukese polümeerikattega tablett (üksikannus) EU/1/09/569/033 98 x 1 õhukese polümeerikattega tablett (üksikannus) EU/1/09/569/034 280 x 1 õhukese polümeerikattega tablett (üksikannus)
English: EU/1/09/569/039 30 film-coated tablets
Estonian: EU/1/09/569/039 30 õhukese polümeerikattega tabletti
English: EU/1/09/569/008 56 x 1 film-coated tablet (unit dose) EU/1/09/569/009 98 x 1 film-coated tablet (unit dose) EU/1/09/569/010 280 x 1 film-coated tablet (unit dose)
Estonian: EU/1/09/569/008 56 x 1 õhukese polümeerikattega tablett (üksikannus) EU/1/09/569/009 98 x 1 õhukese polümeerikattega tablett (üksikannus) EU/1/09/569/010 280 x 1 õhukese polümeerikattega tablett (üksikannus)
English: EU/1/09/569/044 56 x 1 film-coated tablet (unit dose) EU/1/09/569/045 98 x 1 film-coated tablet (unit dose) EU/1/09/569/046 280 x 1 film-coated tablet (unit dose)
Estonian: EU/1/09/569/044 56 x 1 õhukese polümeerikattega tablett (üksikannus) EU/1/09/569/045 98 x 1 õhukese polümeerikattega tablett (üksikannus) EU/1/09/569/046 280 x 1 õhukese polümeerikattega tablett (üksikannus)
English: EU/1/09/569/050 28 film-coated tablets
Estonian: EU/1/09/569/050 28 õhukese polümeerikattega tabletti
English: Exforge HCT 5 mg/160 mg/12.5 mg film-coated tablets The active substances of Exforge HCT are amlodipine (as amlodipine besylate), valsartan and hydrochlorothiazide.
Estonian: Exforge HCT 5 mg/160 mg/12,5 mg õhukese polümeerikattega tabletid Exforge HCT toimeained on amlodipiin (amlodipiinbesülaadina), valsartaan ja hüdroklorotiasiid.
English: Exforge HCT 10 mg/160 mg/25 mg film-coated tablets The active substances of Exforge HCT are amlodipine (as amlodipine besylate), valsartan and hydrochlorothiazide.
Estonian: Exforge HCT 10 mg/160 mg/25 mg õhukese polümeerikattega tabletid Exforge HCT toimeained on amlodipiin (amlodipiinbesülaadina), valsartaan ja hüdroklorotiasiid.
English: EU/1/09/569/020 56 x 1 film-coated tablet (unit dose) EU/1/09/569/021 98 x 1 film-coated tablet (unit dose) EU/1/09/569/022 280 x 1 film-coated tablet (unit dose)
Estonian: EU/1/09/569/020 56 x 1 õhukese polümeerikattega tablett (üksikannus) EU/1/09/569/021 98 x 1 õhukese polümeerikattega tablett (üksikannus) EU/1/09/569/022 280 x 1 õhukese polümeerikattega tablett (üksikannus)
English: Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets The active substances of Exforge HCT are amlodipine (as amlodipine besylate), valsartan and hydrochlorothiazide.
Estonian: Exforge HCT 10 mg/160 mg/12,5 mg õhukese polümeerikattega tabletid Exforge HCT toimeained on amlodipiin (amlodipiinbesülaadina), valsartaan ja hüdroklorotiasiid.
English: Exforge HCT 5 mg/160 mg/12.5 mg film-coated tablets amlodipine/valsartan/hydrochlorothiaziade
Estonian: Exforge HCT 5 mg/160 mg/12,5 mg õhukese polümeerikattega tabletid amlodipinum/valsartanum/hydrochlorothiazidum
English: Exforge HCT 5 mg/160 mg/25 mg film-coated tablets amlodipine/valsartan/hydrochlorothiaziade
Estonian: Exforge HCT 5 mg/160 mg/25 mg õhukese polümeerikattega tabletid amlodipinum/valsartanum/hydrochlorothiazidum
English: Exforge HCT 10 mg/160 mg/25 mg film-coated tablets amlodipine/valsartan/hydrochlorothiaziade
Estonian: Exforge HCT 10 mg/160 mg/25 mg õhukese polümeerikattega tabletid amlodipinum/valsartanum/hydrochlorothiazidum
English: Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets amlodipine/valsartan/hydrochlorothiaziade
Estonian: Exforge HCT 10 mg/160 mg/12,5 mg õhukese polümeerikattega tabletid amlodipinum/valsartanum/hydrochlorothiazidum
English: EU/1/09/569/013 14 film-coated tablets
Estonian: EU/1/09/569/013 14 õhukese polümeerikattega tabletti
English: EU/1/09/569/028 56 film-coated tablets
Estonian: EU/1/09/569/028 56 õhukese polümeerikattega tabletti
English: EU/1/09/569/036 280 film-coated tablets (multipack, 20 cartons of 14 tablets) EU/1/09/569/035 280 film-coated tablets (multipack, 4 cartons of 70 tablets) (unit dose)
Estonian: EU/1/09/569/036 280 õhukese polümeerikattega tabletti (hulgipakend, 20 karpi, igaühes 14 tabletti) EU/1/09/569/035 280 õhukese polümeerikattega tabletti (hulgipakend, 4 karpi, igaühes 70 tabletti) (üheannuseline)
English: Frequency Exforge HCT
Estonian: Exforge HCT üksik-komponent
English: EU/1/09/569/048 280 film-coated tablets (multipack, 20 cartons of 14 tablets) EU/1/09/569/047 280 film-coated tablets (multipack, 4 cartons of 70 tablets) (unit dose)
Estonian: EU/1/09/569/048 280 õhukese polümeerikattega tabletti (hulgipakend, 20 karpi, igaühes 14 tabletti) EU/1/09/569/047 280 õhukese polümeerikattega tabletti (hulgipakend, 4 karpi, igaühes 70 tabletti) (üheannuseline)
English: EU/1/09/569/012 280 film-coated tablets (multipack, 20 cartons of 14 tablets) EU/1/09/569/011 280 film-coated tablets (multipack, 4 cartons of 70 tablets) (unit dose)
Estonian: EU/1/09/569/012 280 õhukese polümeerikattega tabletti (hulgipakend, 20 karpi, igaühes 14 tabletti) EU/1/09/569/011 280 õhukese polümeerikattega tabletti (hulgipakend, 4 karpi, igaühes 70 tabletti) (üheannuseline)
English: EU/1/09/569/060 280 film-coated tablets (multipack, 20 cartons of 14 tablets) EU/1/09/569/059 280 film-coated tablets (multipack, 4 cartons of 70 tablets) (unit dose)
Estonian: EU/1/09/569/060 280 õhukese polümeerikattega tabletti (hulgipakend, 20 karpi, igaühes 14 tabletti) EU/1/09/569/059 280 õhukese polümeerikattega tabletti (hulgipakend, 4 karpi, igaühes 70 tabletti) (üheannuseline)
English: EU/1/09/569/024 280 film-coated tablets (multipack, 20 cartons of 14 tablets) EU/1/09/569/023 280 film-coated tablets (multipack, 4 cartons of 70 tablets) (unit dose)
Estonian: EU/1/09/569/024 280 õhukese polümeerikattega tabletti (hulgipakend, 20 karpi, igaühes 14 tabletti) EU/1/09/569/023 280 õhukese polümeerikattega tabletti (hulgipakend, 4 karpi, igaühes 70 tabletti) (üheannuseline)
English: Serum levels of calcium should be periodically monitored during treatment with thiazides.
Estonian: Kui ravi ajal tekib hüperkaltseemia, tuleb ravi Exforge HCT'ga katkestada.Ravi ajal tiasiiddiureetikumidega tuleb seerumi kaltsiumitaset perioodiliselt jälgida.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/18/1290/001
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/18/1290/001
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 26 July 2018
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE/MÜÜGILOA UUENDAMISE KUUPÄEV Müügiloa esmase väljastamise kuupäev: 26. juuli 2018
English: Frequency is defined as very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Estonian: Esinemissagedust määratletakse kui väga sage (≥ 1/10), sage (≥ 1/100 kuni < 1/10), aeg-ajalt (≥ 1/1000 kuni < 1/100), harv (≥ 1/10 000 kuni < 1/1000), väga harv (< 1/10 000), teadmata (ei saa hinnata olemasolevate andmete alusel).
English: Other medicines and Nityr
Estonian: Muud ravimid ja Nityr
English: Each bottle contains 60 tablets.
Estonian: Igas pudelis on 60 tabletti.
English: Treatment of all genotypes of the disease should be initiated as early as possible to increase overall survival and avoid complications such as liver failure, liver cancer and renal disease.
Estonian: Kõigi haiguse genotüüpide ravi tuleb alustada nii varakult kui võimalik, et suurendada üldist elulemust ning vältida tüsistusi nagu maksapuudulikkus, maksavähk või neeruhaigus.
English: No formal interaction studies with other medicinal products have been conducted.
Estonian: Formaalseid koostoimete uuringuid teiste ravimitega ei ole teostatud.
English: Each carton contains 1 bottle.
Estonian: Igas pakendis on 1 pudel.
English: MedDRA system organ class
Estonian: MedDRA organsüsteemi klass Esinemissagedus
English: If the biochemical response is satisfactory, the dose should be adjusted only according to body weight gain.
Estonian: Kui biokeemiline reaktsioon ravimile on rahuldav, tuleb annust kohandada üksnes vastavalt kehakaalu suurenemisele.